References
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117–171.
- Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191.
- Mendis S. Stroke disability and rehabilitation of stroke: world health organization perspective. Int J Stroke. 2013;8(1):3–4.
- Wieloch T, Nikolich K. Mechanisms of neural plasticity following brain injury. Curr Opin Neurobiol. 2006;16:258–264.
- Nudo RJ. Recovery after brain injury: mechanisms and principles. Front Hum Neurosci. 2013;7:887.
- Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–130.
- Corbett D, Jeffers M, Nguemeni C, et al. Lost in translation: rethinking approaches to stroke recovery. Prog Brain Res. 2015;218:413–434.
- Perez C, Morales-Quezada L, Fregni F. A combined therapeutic approach in stroke rehabilitation: a review on non-invasive brain stimulation plus pharmacotherapy. Int J Neurorehabil. 2014;1(3):123.
- Gower A, Tiberi M. The intersection of central dopamine system and stroke: potential avenues aiming at enhancement of motor recovery. Front Synaptic Neurosci. 2018;10:18.
- Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.
- Sprigg N, Bath PM. Speeding stroke recovery? A systematic review of amphetamine after stroke. J Neurol Sci. 2009;285(1–2):3–9.
- Yeo SH, Lim ZI, Mao J, et al. Effects of central nervous system drugs on recovery after stroke: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2017;37(10):901–928.
- Cramer SC, Dobkin BH, Noser EA, et al. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Stroke. 2009;40:3034–3038.
- Cramer SC. Drugs to enhance motor recovery after stroke. Stroke. 2015;46:2998–3005.
- Calabrò RS, Naro A, De Luca R, et al. PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study! Aging Clin Exp Res. 2016;28(6):1279–1282.
- Caltagirone C, Cisari C, Schievano C, et al. Stroke Study Group. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016;7(1):54–69.
- FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393(10168):265–274.
- Calabrò RS, Russo M, Naro A, et al. Who may benefit from armeo power treatment? A Neurophysiological approach to predict neurorehabilitation outcomes. PM&R. 2016;8(10):971–978.